Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad has maintained an Overweight rating on Teva Pharmaceutical Industries (NYSE:TEVA) and increased the price target from $14 to $15.
January 29, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Balaji Prasad maintains an Overweight rating on Teva Pharmaceutical Industries and raises the price target from $14 to $15.
The increase in price target by Barclays reflects a positive outlook on Teva Pharmaceutical Industries, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100